Treatment, pathological characteristics, and prognosis of pulmonary inflammatory myofibroblastic tumor—a retrospective study of 8 cases

Xiao Zhu1†, Wen-Bang Chen1†, Fu-Bao Xing1, Shao Zhou1, Zhen Tang1, Xiao-Jun Li1, Lei Zhang1* and Yu-Chen Huang2

1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 2Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

Objective: Inflammatory myofibroblastic tumor (IMT) is a rare disease. We reviewed data from eight patients diagnosed with pulmonary IMT (PIMT) at our hospital with the aim of summarizing and analyzing the characteristics of PIMT to improve our understanding of the disease.

Methods: From January 2012 to December 2019, eight patients underwent surgical intervention for PIMT at The First Affiliated Hospital of Bengbu Medical College. Resected tumors were subjected to pathological and immunohistochemical analyses. The follow-up duration for all patients ranged from 2 years and 3 months to 9 years and 9 months (median: 6 years and 9 months).

Results: The male:female ratio was 5:3, and the mean age was 48.50 years (21–74 years). Two patients (25%) with lung disease discovered via chest computed tomography during physical examinations had not experienced any symptoms. Six patients (75%) presented at the hospital because of cough, expectoration, blood in sputum, and chest tightness. Lesions from all eight patients were surgically removed, and PIMT was confirmed based on pathological examinations and immunohistochemical results. No patient received additional treatment after discharge. All cases have been followed up to the time of writing, without any tumor recurrence or distant metastasis.

Conclusion: The age of onset of PIMT is usually over 40 years, and its clinical symptoms are easily confused with those of lung cancer. PIMT can only be diagnosed by histopathology and immunohistochemistry. Complete surgical resection is the preferred treatment, as patients undergoing surgery require no additional treatment, such as chemotherapy, and the survival rate is good.

KEYWORDS
lung tumor, lung cancer, pathological characteristics, pulmonary inflammatory myofibroblastic tumor, prognosis
Introduction

Inflammatory myofibroblastic tumor (IMT) is a rare disease. In 2020, the World Health Organization (WHO) identified IMT as a borderline tumor with potentially recurrent and rare metastatic properties (1). The most common site of IMT is the lung, although it can also occur in the abdomen, pelvis, head and neck, upper respiratory tract, limbs, lumbar tube, uterus, and other sites (2–6). To date, the etiology of IMT remains inconclusive, although recent studies have shown that IMT is associated with anaplastic lymphoma kinase (ALK) gene rearrangements, as well as overexpression of ALK protein, and the disease also involves fusion of genes such as ROS1, NTRK3, and RET (7–10). Furthermore, a fraction of IMT cases are associated with chromosomal abnormalities (11). The diagnosis of pulmonary IMT (PIMT) is rare and such cases account for only 0.04–0.7% of all lung masses (2, 12–14). Globally, there are very few studies related to PIMT. Therefore, to analyze and improve the understanding of the pathological characteristics, treatment modalities, and prognosis of PIMT, we aimed to review the data collected from a group of patients diagnosed with PIMT at our hospital and to review the literature related to such cases published in recent years.

Material and methods

Subjects

We reviewed the data of eight patients diagnosed with PIMT by histopathology and immunohistochemistry at The First Affiliated Hospital of Bengbu Medical College between January 2012 and December 2019, including information on clinical symptoms, treatment modalities, pathological features, and prognosis. Examinations conducted prior to surgery included laboratory examinations and computed tomography (CT) scans. In addition, to determine whether there is distant metastases of the tumor, we also performed cranial magnetic resonance imaging (MRI), bone emission computed tomography (ECT), and abdominal ultrasound on patients. None of these examination findings were abnormal.

Histology and immunohistochemistry

After surgery, tumor specimens from each case were fixed with 10% neutral formaldehyde solution, extracted, paraffin-embedded, cut into 4-μm continuous sections, stained with hematoxylin and eosin (HE), and subjected to immunohistochemistry (EnVision; Agilent Technologies, Santa Clara, CA). The follow-up time ranged from 2 years and 3 months to 9 years and 9 months.

Ethical approval

This study was conducted with approval from the Ethics Committee of The First Affiliated Hospital of Bengbu Medical College. Written informed consent was obtained from the participants.

Results

The clinical data of the eight patients included in the study are presented in Table 1. Among the eight patients, the male:female ratio was 5:3, and the mean age was 48.50 years (range: 21–74 years). Two patients (25%) with lung disease discovered by chest CT during a physical examination had experienced no symptoms. Six patients (75%) presented to the hospital because of cough, expectoration, blood in sputum, and chest tightness. Chest CT of the patients revealed a tumor diameter ranging from 2–4 cm (Figures 1 and 2). None of the patients had a long-term history of respiratory tract infections.

A lobectomy was performed on all patients, resulting in successful tumor removal. None of the patients received additional treatment after discharge. There has been no tumor recurrence or distant metastasis in any patient to date.

Among these patients, the largest tumor was 4 cm in diameter and the smallest was 2 cm in diameter, with an average of 2.95 cm. The tumors were mainly composed of spindle cells, with surrounding chronic inflammatory cell infiltration (Figure 3). In terms of immunohistochemical results, the following characteristics were observed: ALK labeling was positive in five cases (Figure 4), vimentin (VIM) labeling was positive in all eight cases (Figure 5), seven cases exhibited positive smooth muscle actin (SMA) labeling (Figure 6), one case demonstrated positive calponin labeling (Figure 7), and six cases showed positive Ki67 labeling (Figure 8). All eight patients were diagnosed with PIMT according to pathological features and immunohistochemistry results, and there was no lymph node metastasis.

Discussion

IMT can occur at any age, although it most commonly occurs in young people, and there is no significant sex bias (2, 15–17). However, the mean age of our patients was 48.5 years, which is quite different from that reported in the literature. We believe this may be because the literature reports the mean age of patients with IMT at all body sites, whereas the present study only evaluated the characteristics of patients with PIMT specifically. In addition, in this study, there was no sex bias, which is consistent with previous reports.
The presence of cough, hemoptysis, and other symptoms reported by patients in this study support the view that the clinical manifestations of PIMT can be easily confused with lung cancer and tuberculosis (7). In X-ray and CT examinations, most cases of PIMT manifest as individual masses in the lung. The density inside the mass is basically uniform, and its boundaries tend to be clear, although lobulation and burr signs are occasionally seen (18), which is consistent with the CT characteristics of the patients in this study. Therefore, CT cannot distinguish PIMT from lung cancer. Although PIMT has also been reported in studies involving positron emission tomography (PET)/CT, spectral CT, magnetic resonance imaging (MRI), and other imaging methods (19, 20), imaging modalities alone cannot diagnose PIMT. Some scholars have reported that IMT has been misdiagnosed as lymphoma by PET/CT (21).

Pathology and immunohistochemistry are the most accurate methods for diagnosing IMT (20). Under the microscope, IMT is characterized by a series of myofibroblast proliferations and different types of inflammatory cell infiltration (14), which is consistent with the findings of this study. Most IMT immunohistochemistry has shown that spindle tumor cells were positively labeled by VIM, SMA, and ALK antibodies; more specifically, VIM labeling is usually strongly positive and diffusely observed in the cytoplasm of spindle cells, SMA labeling is mostly focal or diffusely positive, and ALK protein is expressed in 50–60% of cells (8). These immunohistochemical characteristics were also observed in the eight patients in this study. Therefore, we believe that VIM, SMA, and ALK are the three most important markers for the diagnosis of IMT by immunohistochemistry.

Although there are many ways to treat PIMT, surgical resection remains the first choice (14, 22). Although intraoperative frozen sections were collected in all cases, whether the tumors were benign or malignant could not be completely determined. At the same time, considering the clinical characteristics, CT results, and deep locations of the tumors, lobectomy was performed for all patients. In seven cases, the result of rapid frozen-section pathology was indicative of inflammatory myofibroblastoma. Therefore, only lobectomy was performed. In one case, the result of rapid frozen-section pathology was indicative of IMT, but the possibility of a malignant tumor was not ruled out, so a lobectomy with lymph node dissection was performed. Casanova and colleagues (23) believe that the prognosis of patients with PIMT who undergo early surgery is usually ideal, and there is no need for adjuvant treatment such as chemotherapy. Our results are consistent with this assertion, and none of the patients received additional treatment after discharge. To date, there have been no recurrences or distant metastases.

We performed lymph node dissection in one patient and the result was negative. There is no definitive conclusion regarding whether lymph node dissection should be conducted in patients with PIMT. Some researchers have found the existence of cancer stem cells in PIMT tissues (24), and some studies have reported

| Case | Sex/age (years) | Symptoms | Location/size | Surgery | Prognosis after surgery | Results of positive immunohistochemistry |
|------|----------------|----------|---------------|---------|-------------------------|---------------------------------------|
| 1    | M/38           | Cough/ Hemoptysis | RLL/3.0 cm   | Lobectomy | 9 years 9 months, alive | ALK(++), Vim(+) SMA(+) Calponin(+) Ki67(+) |
| 2    | F/42           | Cough/ Hemoptysis | RUL/2.0 cm   | Lobectomy | 9 years, alive         | ALK(+), Vim(+), SMA(-), Calponin(-), Ki67(+) |
| 3    | F/46           | None       | RUL/2.5 cm    | Lobectomy | 7 years, alive         | ALK(+), Vim(+), SMA(-), Calponin(-), Ki67(+) |
| 4    | M/50           | None       | RML/3.0 cm    | Lobectomy | 7 years, alive         | ALK(-), Vim(+++), SMA(-/+), Calponin(-), Ki67(+) |
| 5    | M/52           | None       | RLL/2.8 cm    | Lobectomy | 6 years, alive         | ALK(-), Vim(+++), SMA(-/+), Calponin(-), Ki67(+) |
| 6    | M/59           | None       | LLL/2.0 cm    | Lobectomy | 4 years, alive         | ALK(-), Vim(++) SMA(-), Calponin(-), Ki67(+) |
| 7    | M/67           | None       | RUL/1.0 cm    | Lobectomy | 2 years, alive         | ALK(-), Vim(++) SMA(-), Calponin(-), Ki67(+) |
| 8    | F, female, M/74 | Thoracalgia | RUL/4.0 cm    | Lobectomy+ lymph node dissection | 2 years, alive | ALK(-), Vim(+++), SMA(++) Calponin(+) Ki67(+) |

F, female; M, male; RLL, right lower lobe; RUL, right upper lobe; RML, right middle lobe; LLL, left lower lobe; RML, right middle lobe; ALK, anaplastic lymphoma kinase; Vim, vimentin; SMA, smooth muscle actin.
that the lymph nodes removed during surgery in patients with PIMT were positive (23). In addition, cervical lymph node metastasis has occurred 3.5 years post-operation (25). Moreover, the WHO points out that IMT is a borderline tumor with the potential for recurrence and rare metastasis. Based on the above aspects, we suggest that lymph node dissection should be performed if the pathological results of intraoperative frozen sectioning suggest PIMT. However, the current sample size is small, and there is still a lack of research in this field. More studies must be conducted in the future to verify the necessity of lymph node dissection in these patients.

The prognosis of patients with PIMT is good (22, 23), with a 5-year survival rate of 91.3% and a 10-year survival rate of 77% (2). Studies have found that all metastatic IMTs are ALK-negative, and ALK positivity may be a good prognostic indicator of IMT (26). However, the latest research by Casanova and colleagues (23) shows that even patients who cannot undergo surgery and those who are ALK-negative have
a good prognosis. Regardless of whether ALK labeling was positive or not, the eight patients whose data we reviewed experienced no recurrence or metastasis after surgery, which was consistent with the results of Casanova et al. (23). Some patients with IMT who have tumor tissue removed still experience relapse and distant metastasis (25–27). In one study, researchers followed up 23 patients after PIMT excision for 2–127 months; in those cases, recurrence only occurred twice after operation, and there was no recurrence after reoperation (28). If only local recurrence occurs and the patient’s physical condition is good, reoperation is still recommended (7). Systemic therapy is reserved for patients with unresectable, progressive or metastatic disease and whose body is unable to withstand lobectomy. There is controversy regarding the treatment of PIMT with steroids. On the one hand, as early as 1991, the treatment of PIMT with steroids was reported (29), and on the other hand there are reports that steroids may have an enhancing effect on IMT cell proliferation (30). In addition,
there are also some reports on non-steroidal anti-inflammatory drugs (NSAID) treatment for PIMT that are ALK-negative (31). Chemotherapy is a valid option for advanced IMT (23). One study has confirmed that Anthracycline-based and methotrexate plus/minus vinorelbine/vinblastine (MTX-V) regimens are very effective in IMT (17). Studies have reported the cases of using radiotherapy for recurrence of surgical resection (25), but currently there is no sufficient evidence to prove the efficacy of radiotherapy. There are reports that gene-targeted drugs are used to treat IMT (32–40). The US National Comprehensive Cancer Network recommends the use of crizotinib as the standard of care for IMT with ALK-positive (36). Ceritinib, a second-generation ALK inhibitor, has also been shown to be effective in IMT (41).

**Conclusion**

PIMT is a rare tumor type. Due to the lack of specificity in clinical and imaging manifestations, the diagnosis
of PIMT can only be made based on pathology and immunohistochemistry results. Complete surgical resection is the preferred treatment in such cases and usually results in satisfactory outcomes. Because local recurrence and metastasis is possible in some cases of IMT, we recommend close, long-term follow-up. Because the disease is rare and the sample size of this study is small, the views described in this paper need to be supported by more research, such as multicenter and large-sample studies to provide more concrete clinical recommendations.
Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of The First Affiliated Hospital of Bengbu Medical College. The patients/participants provided their written informed consent to participate in this study.

Author contributions

XZ, WBC and LZ performed the surgeries, reviewed the literature, and contributed to manuscript drafting; FBX, SZ, and XJL reviewed the literature and contributed to manuscript drafting; and XJL and YCH were responsible for the revision of the manuscript for important intellectual content. All authors issued final approval for the version to be submitted.

References

1. Choi JH, Ro JY. The 2020 WHO classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol (2021) 28(1):44–58. doi: 10.1097/PAP.0000000000000284
2. Hussain SF, Salahuddin N, Khan A, Memon SSJ, Fatimi SH, Ahmed R. The insidious onset of dyspnea and right lung collapse in a 35-year-old man. Chest (2005) 127(5):1844–7. doi: 10.1378/chest.127.5.1844
3. Dehner LP. The enigmatic inflammatory pseudotumours: the current state of our understanding, or misunderstanding. J Pathol (2000) 192(3):277–9. doi: 10.1002/1096-9896(200011)192:3<277::AID-PATH649>3.0.CO;2-E
4. Coffin CM, Waterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol (1995) 19(8):859–72. doi: 10.1097/00000478-199508000-00001
5. Wang S, Chen L, Cao Z, Mao X, Zhang L, Wang B. Inflammatory myofibroblastic tumor of the lumbar spinal canal: a case report with literature review. Med (Baltim) (2017) 96(26):e6488. doi: 10.1097/MD.0000000000006488
6. Bennett JA, Croce S, Pesci A, Niu N, Van de Vijver K, Burks EJ, et al. Inflammatory myofibroblastic tumor of the uterus: an immunohistochemical study of 23 cases. Am J Surg Pathol (2020) 44(11):1441–9. doi: 10.1097/PAS.0000000000001255
7. Proshvazheasukaya EV, Iyerleva AG, Saleymanova AM, Tsiurn VL, Mitsuhashi NY, Buzin IV, et al. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. Pediatr Blood Cancer (2020) 67(5):e28220. doi: 10.1002/pbc.28220
8. Chang IC, Zhang L, DeCion AE, Chi P, Alaggio R, Borou L, et al. Expanding the molecular characterization of thoracic inflammatory myofibroblastic tumors beyond ALK gene rearrangements. J Thorac Oncol (2019) 14(5):825–34. doi: 10.1016/j.jtho.2018.12.003
9. Yamamoto H, Yoshida A, Taguchi K, Kothari K, Hatanaka Y, Yamashita A, et al. ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology (2016) 69(1):72–83. doi: 10.1111/his.12910
10. Alasrri AH, Ali RH, Shy Y, Lum A, Straehlend C, Deyell R, et al. ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors. Am J Surg Pathol (2018) 42(8):1051–61. doi: 10.1097/PAS.0000000000000677
11. Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. Inflammatory myofibroblastic tumor of the lung. Adv Respir Med (2018) 86(1):27–35. doi: 10.5603/ARM.2018.0007
12. Cerfolio RJ, Allen MS, Nascimento AG, Deschamps C, Trastek VF, Miller DL, et al. Inflammatory pseudotumors of the lung. Ann Thorac Surg (1999) 67(4):933–6. doi: 10.1016/S0003-4975(99)01551-1
13. Sakurai H, Hasegawa T, Wataanabe S, Suzuki K, Asahara H, Tsuchiya R. Inflammatory myofibroblastic tumor of the lung. Eur J Cardiothorac Surg (2004) 25(2):155–9. doi: 10.1016/j.ejcts.2003.06078-x
14. Takeda S, Onishi Y, Kawamura T, Maeda H. Clinical spectrum of pulmonary inflammatory myofibroblastic tumor. Interact Cardiovasc Thorac Surg (2008) 7(4):629–33. doi: 10.1510/icvts.2007.03476
15. Cassivi SD, Wyland ME. Pulmonary inflammatory myofibroblastic tumor associated with histoplasmosis. Interact Cardiovasc Thorac Surg (2006) 5(4):514–6. doi: 10.1510/icvts.2006.129809
16. Meis JM, Enzinger FM. Inflammatory fibrosarcoma of the mesentery and retroperitoneum. a tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol (1991) 15(12):1146–56. doi: 10.1097/00000478-199112000-00005
17. Baldi GG, Brahmi M, Lo Vullo S, Cojocaru E, Mab M, Casanova M, et al. The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter, European retrospective case series analysis. Oncologist (2020) 25(11):e777–84. doi: 10.1634/theoncologist.2020-0352
18. Surabhi VR, Chuu S, Patel RP, Takahashi N, Laiwani N, Prasad SR. Inflammatory myofibroblastic tumors: current update. Radiol Clin North Am (2016) 54(3):553–63. doi: 10.1016/j.rcl.2015.12.005
19. Yu Y, Wang X, Shi C, Hu S, Zhu H, Hu C. Spectral computed tomography imaging in the differential diagnosis of lung cancer and inflammatory myofibroblastic tumor. J Comput Assist Tomogr (2019) 43(2):338–44. doi: 10.1097/RAE.0000000000000840
20. Panagiotopoulos N, Patrini D, Gvinandzidze L, Woo WL, Borg E, Lawrence D. Inflammatory myofibroblastic tumour of the lung: a reactive lesion or a true neoplasm? J Thorac Dis (2015) 7(5):908–11. doi: 10.3978/j.issn.2072-1439.2015.04.60
21. Ma C, Lu J, Chen G, Wang W, Su F, Su X. Inflammatory myofibroblastic tumor mimicking lymphoma on 18F-FDG PET/CT. report of a case and review of the literature. Hell J Nucl Med (2018) 21(1):77–80. doi: 10.1634/theoncologist.2020-0352
